Activation of the cholinergic anti-inflammatory system by nicotine attenuates arthritis via suppression of macrophage migration

SHA LI¹, BIN ZHOU¹, BEN LIU², YAOU ZHOU¹, HUALI ZHANG³, TONG LI¹ and XIAOXIA ZUO¹

Departments of ¹Rheumatology and ²Emergency, Xiangya Hospital, Central South University, Changsha, Hunan 410008; ³Department of Pathophysiology, Xiangya School of Medicine, Central South University, Changsha, Hunan 410008, P.R. China

Received October 3, 2015; Accepted October 13, 2016

DOI: 10.3892/mmr.2016.5904

Abstract. Activation of the cholinergic anti-inflammatory pathway (CAP), which relies on the alpha-7 nicotinic acetylcholine receptor, has been reported to reduce proinflammatory cytokine levels in experimental arthritis. To gain more insight regarding the role of the CAP in the pathogenesis of arthritis, the present study focused on the modulation of macrophage infiltration. In a mouse model of collagen-induced arthritis (CIA), nicotine and vagotomy were used to stimulate and inhibit the CAP, respectively. Subsequently, arthritic scores were measured and histopathological assessment of joint sections was conducted. Cluster of differentiation (CD)11b-positive macrophages in the synovium were studied by immunofluorescence histochemistry. The serum levels of chemokines, including macrophage inflammatory protein (MIP)-1α, monocyte chemoattractant protein (MCP)-1 and MIP-2 were evaluated by ELISA. Furthermore, the expression levels of C-C chemokine receptor (CCR)2 and intercellular adhesion molecule (ICAM)-1 in the synovium were evaluated by immunohistochemical staining. The results indicated that treatment with nicotine significantly attenuated the clinical and histopathological changes associated with arthritis, reduced CD11b-positive macrophages in the synovium, and down-regulated the serum expression levels of MIP-1α and MCP-1. Conversely, vagotomy aggravated arthritis and upregulated the expression levels of MCP-1. However, MIP-2 expression did not differ among the control, CIA, vagotomy and nicotine groups. In addition, the expression levels of CCR2 were reduced in the nicotine group; however, they were increased in the vagotomy group compared with in the untreated CIA group. The expression levels of ICAM-1 in the synovium were also influenced by activation of the CAP. Taken together, the present results indicated that nicotine-induced activation of the CAP in mice with CIA may reduce the number of macrophages in the synovium, which may serve a role in alleviating arthritis in mice.

Introduction

Monocytes and macrophages are critical mediators of rheumatoid arthritis (RA) (1,2). High numbers of macrophages are present in inflamed tissues, particularly at the cartilage-pannus interface in human RA, and have been reported to be correlated with RA severity (3,4). In addition, inhibiting macrophage migration to sites of inflammation may markedly reduce inflammation and tissue destruction (5). Therefore, inhibiting the migration of macrophages is considered a potential key strategy for the treatment of RA. However, macrophage migration is a continuous and complex process, which includes rolling of monocytes along the endothelium, firm adhesion to the endothelium, and transendothelial cell migration. Within macrophage migration, chemotaxis and adhesion are considered the most important processes. Monocytes traverse the endothelium in order to enter developing and established lesions; this trafficking is directed by chemokines, such as macrophage inflammatory protein (MIP)-1α, monocyte chemoattractant protein (MCP)-1 and interleukin (IL)-8. C-C chemokine receptor (CCR)1, CCR2 and CXC chemokine receptor 2 are considered classical chemokine receptors, which have been proposed to affect monocyte recruitment in mouse models of arthritis (6-8). In addition, the firm adhesion of monocytes is mediated via the endothelial expression of members of the immunoglobulin superfamily, such as intercellular adhesion molecule (ICAM)-1, and their counter-ligands, which are expressed by leukocytes, including cluster of differentiation (CD)11b/CD18.

The cholinergic anti-inflammatory pathway (CAP), which transmits information from the brain to the peripheral immune system via the parasympathetic nervous system, was initially described in 2000 (9). Cholinergic stimulation, by vagus nerve electrical stimulation or treatment with selective cholinergic agonists, suppresses the production of cytokines in preclinical models of systemic inflammation, including endotoxemia, hemorrhagic shock, ischemia-reperfusion injury and acute lung injury (9-11). Macrophages express alpha-7 nicotinic acetylcholine receptor, pharmacological stimulation...
of which reduces the production of inflammatory cytokines by macrophages (12,13). In previous experiments by authors of the present study, and others, the CAP has been revealed to exert a protective effect on RA (14-16); the underlying mechanism may be associated with the inhibition of T helper (Th)17 cell responses and may improve the Th1/Th2 imbalance in collagen-induced arthritis (CIA). However, the specific mechanisms remain unclear.

The present study established that reduced numbers of macrophages are present in synovial tissues following activation of cholinergic signaling, since synovial tissues are not innervated by the vagus nerve. The present study aimed to elaborate the protective effects of the CAP on RA and to elucidate its cellular molecular mechanisms, thus providing an experimental basis regarding how the CAP regulates inflammatory and immune responses in RA.

Materials and methods

Mice. A total of 56 male DBA/1 mice (weight, 20 g; age, 6-8 weeks; 24 mice died prematurely whilst the model was established) were purchased from the SJA Laboratory Animal Co. (Shanghai, China) for use in the CIA studies. The mice were housed under specific-pathogen-free conditions at 24-28°C, 40-70% humidity, 12 h light/dark cycle and free access to food and water. The animal experiments were performed in accordance with the institutional guidelines for animal care, and were approved by the committee for the use and care of animals at Central South University (Changsha, China).

Experimental groups. The mice were randomly divided into four groups (n=8): Control group [sham vagotomy + phosphate-buffered saline (PBS)], model group (sham vagotomy + CIA + PBS), vagotomy group (vagotomy + CIA + PBS), and nicotine group (sham vagotomy + CIA + nicotine). To inhibit the CAP, mice in the vagotomy group were subjected to left-side cervical vagotomy 4 days prior to CIA induction (14). In sham-operated mice, the left vagus nerve was exposed and isolated from the surrounding tissue but was not transected. In the nicotine group, the peripheral segment of the CAP was stimulated by intraperitoneal pretreatment with nicotine daily (250 µg/kg; Sigma-Aldrich; Merck Millipore, Darmstadt, Germany), beginning 4 days prior to CIA induction. The other groups were injected with PBS as a control.

Induction and evaluation of CIA. CIA was induced in the DBA/1 mice as previously described (14). Bovine type II collagen (2 mg/ml; Chondrex, Inc., Redmond, WA, USA) was emulsified in an equal volume of Freund’s complete adjuvant (containing 4 mg/ml Mycobacterium tuberculosis; Chondrex, Inc.) at 4°C by magnetic stirring until fully emulsified. The final concentration of collagen was 1 mg/ml. All male DBA/1 mice, with the exception of the control mice, were initially immunized intracutaneously at the base of the tail with 0.1 ml of this emulsion (100 µg collagen). On day 21, the mice were administered booster injections of 0.1 ml emulsion in Freund’s incomplete adjuvant (Chondrex, Inc.) in the same manner.

Clinical signs of arthritis in the joints were visually assessed every 3 days by two observers. All animals were regularly examined for signs of arthritis, and the disease severity for each paw was graded on a scale between 0 and 4, according to the levels of erythema, swelling and induration. Arthritis index score criteria were as follows: 0, no redness or swelling of the joints; 1, red or slight swelling; 2, moderate swelling; 3, severe swelling; and 4, severe swelling and unloadable. Assessment of incidence and macroscopic score were carried out by two independent observers, without knowledge of the experimental groups. The total arthritic score per mouse was derived from the sum of the individual scores of four paws. Two independent observers without knowledge of the experimental groups assessed the incidence and macroscopic score.

Immunohistochemical evaluation of CIA. The mice were sacrificed by cervical dislocation on day 42, and their hind paws were collected. The joint tissues were fixed in 4% paraformaldehyde overnight at room temperature, decalcified in 13% ethylenediamine tetra-acetic acid for 2-3 weeks and embedded in paraffin and cut into 5 μm sections. The sections (2.5x2.5 cm) were then dewaxed using xylene, dehydrated using an alcohol gradient, and were stained with hematoxylin and eosin (H&E) for 1 min at room temperature for histological assessment. Arthritis severity in histological samples was determined by cumulative assessment of synovial inflammation. The scoring was: 0, normal; 1, minimal; 2, mild; 3, moderate; 4, marked; and 5, severe. This was completed by two independent observed, without knowledge of the experimental groups. Histopathological sections of the hind paws were examined for hyperplasia of the synovial membrane, infiltration with mononuclear cells, and cartilage and bone damage (14).

For immunofluorescence detection of macrophage infiltration, sections were dewaxed and dehydrated as aforementioned. Slides were retrieved using a heat-mediated retrieval method, and endogenous peroxidase activity was quenched with 3% H2O2 for 5 min at room temperature. The sections were then blocked with 3% bovine serum albumin (Sijiqing, Hanzhou, China) for 1 h at room temperature and were incubated overnight at 4°C with an anti-CD11b primary antibody (1:200; cat. no. 101213; BioLegend, San Diego, CA, USA). Subsequently, the sections were incubated with Alexa Fluor 555-conjugated goat anti-rat immunoglobulin G (IgG; cat. no. A-21434; 1:150; Molecular Probes; Thermo Fisher Scientific, Inc., Waltham, MA, USA) and an anti-CD11b primary antibody (1:200; cat. no. A7016; Biyuntian, Shanghai, China) at 4°C overnight. Subsequently, the samples were washed three
times for 5 min in PBS and were incubated with biotin-conjugated goat anti-rabbit IgG (ABC kit; cat. no. PK-6100; Vector Laboratories, Burlingame, CA, USA) for 2 h at room temperature. After three 5-min washes in PBS, the sections were incubated with an avidin-biotinylated enzyme complex (ABC kit; Vector Laboratories) for 2 h at room temperature. Positive signals were visualized using a diaminobenzidine kit (Vector Laboratories), the sections were counterstained with hematoxylin, images were captured using an Olympus microscope (IMT-2, Olympus Corporation, Tokyo, Japan) and were analyzed using Image-Pro Plus 6.0 software (Media Cybernetics, Inc., Rockville, MD, USA).

Chemokine quantification by ELISA. On experimental day 42, the mice were sacrificed, and serum samples were harvested. Whole blood samples (0.8-1 ml each) were centrifuged at 12,000 x g for 20 min at 4°C. The serum levels of MIP-1α (cat. no. MMA00; R&D Systems, Inc., Minneapolis, MN, USA), MCP-1 (cat. no. 81-BMS6005; eBioscience, Inc., San Diego, CA, USA) and MIP-2 (cat. no 70-EK21422; Multiscience Biotech, Co., Ltd., Hangzhou, China) were measured using ELISA kits, according to the manufacturers’ protocols.

Isolation of mononuclear cells and flow cytometry. Spleen samples were obtained from the sacrificed mice. Splenocytes were separated from the spleen using lymphocyte-separation medium (Histopaque®-1119; Sigma-Aldrich; Merck Millipore) after filtering the samples with a cell strainer (BD Biosciences, Franklin Lakes, NJ, USA). Briefly, the cells were incubated for 1 h at 4°C with phycoerythrin-conjugated anti-CD11b (eBioscience, Inc.) or the respective isotype control (cat. no. 12-4031; eBioscience, Inc.). The cells were

![Figure 1](image-url)
then washed with PBS and resuspended in 100 µl PBS for flow cytometric analysis (BD FACS Canto II; BD Biosciences). The data were analyzed using FlowJo software version 9.9.4 (FlowJo, LLC, Ashland, OR, USA).

Statistical analysis. Data were analyzed using GraphPad Prism software version 6.0 (GraphPad Software, Inc., La Jolla, CA, USA) and are presented as the mean ± standard deviation. The experiments were repeated twice. The significance of differences between groups was determined by one-way analysis of variance followed by a multiple comparisons test (Student-Newman-Keuls). The Kruskal-Wallis test was used to determine the heterogeneity of variance. P<0.05 was considered to indicate a statistically significant difference.

Results

Nicotine attenuates the clinical and histopathological changes associated with CIA. The CIA model was induced as aforementioned. The arthritis index score was recorded by two researchers every 3 days after the second immunization until the mice were sacrificed. Slight swelling could be observed in the vagotomy group beginning at day 24, and reaching a peak at day 42. The model group began to present with arthritic symptoms at day 27, with symptoms peaking after 42 days. Arthritis developed slowly and was milder in the nicotine group (Fig. 1A). The histopathological features of the four groups were assessed by H&E staining. The results were consistent with the aforementioned findings, in that the histopathological changes in the nicotine group were reduced, as detected by decreased synovial proliferation, inflammatory cell infiltration and bone destruction (Fig. 1B). Semi-quantitative analysis of the histopathological features is presented in Fig. 1C.

Nicotine reduces macrophage infiltration in the synovium and spleen of CIA mice. Since the present study suggested that nicotine attenuates clinical arthritis and restrains cytokine production, such as TNF-α in our previous study (14), it was
determined whether nicotine can modulate macrophage infiltration in the synovium and spleen. Macrophage infiltration serves a critical role in modulating the immune responses. In mice, the CD11b antigen, as a marker of monocytes/macrophages, is highly expressed on monocytes, macrophages, and to a lesser extent, on granulocytes and a subset of dendritic cells. The present study detected the distribution of CD11b-positive macrophages in the synovium and spleen. Immunofluorescence analysis detected an increase in infiltrated CD11b-positive macrophages in the synovium of the model, vagotomy and nicotine groups, as compared with in the control group. However, among the model, vagotomy and nicotine groups, the percentage of CD11b-positive macrophages was lowest in the nicotine group (Fig. 2A and B). In addition, the percentage of CD11b-positive cells was detected among the splenic mononuclear cells in the four groups, using flow cytometry (Fig. 2C and D). In the model group, the percentage of CD11b-positive cells was increased compared with in the control group. Treatment with nicotine significantly reduced the percentage of CD11b-positive cells in the spleen, as compared with in the model and vagotomy groups.

Nicotine suppresses the serum levels of MIP-1α and MCP-1, but not MIP-2. Chemokines serve a key role in the process of leukocyte extravasation. To determine whether the CAP affects chemotaxis of macrophages in the CIA model, the present study detected the expression levels of the macrophage-associated chemokines MIP-1α, MCP-1 and MIP-2, which have been reported to have major roles in the trafficking of monocytes toward synovial tissue, in the serum of the four groups by ELISA (7,17). Compared with its release in the model and vagotomy groups, nicotine, a classical cholinergic agonist, significantly attenuated release of the...
Nicotine decreases endothelial cell surface levels of ICAM-1 in CIA mice. ICAM-1 has classically been considered to serve a role in intercellular adhesion. To evaluate the effects of nicotine on the expression of adhesion molecules on vascular endothelial cells, ICAM-1 production was measured in the synovium. Immunohistochemical analysis of mouse synovial sections revealed that ICAM-1 was highly expressed in the model and vagotomy groups. Conversely, ICAM-1 expression was significantly suppressed in nicotine-treated mice (Fig. 5A-C).

Discussion

Vagally mediated anti-inflammatory action, also known as the CAP, was clearly described by Tracey (19). In previous years, several researches have reported that activation of the CAP suppresses the clinical and histological manifestations of CIA in mice with established disease (14-16,20,21). The underlying mechanisms may be associated with downregulation of the expression of tumor necrosis factor-α and IL-6, inhibition of Th17 cell responses and improvement in the Th1/Th2 imbalance in CIA; however, the specific mechanism underlying the regulatory effects of nicotine on RA remains complex and only partially understood.

Notably, the present results revealed that nicotine treatment reduced the number of CD11b-positive macrophages in the synovium and spleen samples of CIA mice. Synovial macrophages participate in several of the events that direct inflammation, including angiogenic stimulation, leukocyte and lymphocyte recruitment, fibroblast proliferation, and protease secretion, thus resulting in joint destruction (3,22,23). Synovial macrophages are currently considered the most reliable biomarker for disease severity and therapeutic response in RA (24). Therefore, the present findings suggested that the reduced infiltration of macrophages mediated by nicotine may serve an important role in protection against autoimmune arthritis. However, in the present study, the mice in the vagotomy group were subjected to left-side cervical vagotomy 4 days prior to CIA induction, the vagotomy did not exacerbate CIA-associated inflammation, which may be attributed to a compensatory role for the other side of the vagus nerve. This finding was consistent with the results of previous studies (15,16).

Macrophage infiltration is a process that involves complex and consecutive changes. Monocyte transmigration through endothelial monolayers is directed by chemotaxis, which is a crucial step in the process of complete monocyte recruitment to the vascular wall. The present study demonstrated that nicotine treatment in a CIA model reduced the production of MIP-1α and MCP-1. MIP-1α, which belongs to the CC chemokine family, is chemotactic for monocytes and lymphocytes in RA. MIP-1α may be considered one of the major cytokines that contributes to the chemotraction and retention of RA macrophages in inflamed joints (25). MCP-1, another CC chemokine, was initially identified as a monocyte-specific chemottractant, and has also been reported to serve a role in T-cell differentiation and angiogenesis (26), which may be important in RA pathogenesis. Treatment with an MCP-1 antagonist has been reported to ameliorate disease severity in adjuvant-induced arthritis by decreasing macrophage chemokines MIP-1α and MCP-1 (Fig. 3A and B), but not MIP-2 (Fig. 3C).

Nicotine treatment results in reduced CCR2 expression in the synovium of CIA mice. Chemokines control the directed movement of cells expressing their respective receptors. The chemokine receptor CCR2 is bound by MCP-1, thus contributing to the migration of monocytes from the bloodstream into the tissue (18). The present study examined CCR2 expression in the synovial tissue by immunohistochemistry. The results of a semi-quantitative analysis indicated that CCR2 was highly expressed on synoviocytes in mice with CIA but not in normal mice, and nicotine treatment reduced CCR2 expression in the CIA mice (Fig. 4A-C).

Figure 5. Reduced ICAM-1 expression in synovial tissues. (A and B) Immunohistochemistry was used to analyze ICAM-1 expression in the synovial tissues of mice. Positive cells were detected by the avidin-biotinylated enzyme complex technique with diaminobenzidine development (A, x200 magnification; B, x400 magnification; black arrow, ICAM-1-positive cells). (C) Mean density of ICAM-1 expression in synovial sections from the four groups analyzed by Image-Pro Plus 6.0 software. Data are presented as the mean ± standard deviation (n=6 mice/group). *P<0.05 vs. the shamVGX + PBS group; #P<0.05 vs. the shamVGX + CIA Nic group. CIA, collagen-induced arthritis; VGX, vagotomy; Nic, nicotine; PBS, phosphate-buffered saline; ICAM-1, intercellular adhesion molecule-1.
CCL2 and CCR2 may play a role in initiating and maintaining joint inflammation in patients with CIA. This study demonstrated that nicotine treatment reduces CCR2 expression, as determined by immunohistochemical semi-quantitative analysis. These results indicated that the interaction between MCP-1/C-C chemokine ligand (CCL)2 and CCR2 may promote macrophage migration into the synovium during CIA. A previous study demonstrated that CCL2-CCR2 signaling may activate p42/44 MAPK and PKC through G proteins to regulate cellular adhesion and motility in macrophages (30). Our studies, however, do not rule out the possibility of more direct evidence of macrophage migration in synovial tissues. Further investigations are required to clarify this point. Other interactions between chemokines and their receptors, such as between MCP-1α/CCL3 and CCR1, may also contribute to macrophage migration (32).

ICAM-1 is an adhesion molecule expressed by activated endothelial cells, which is believed to mediate leukocyte migration across the endothelium. However, the potential effects of nicotine on adhesion molecule expression remain controversial. Takahashi et al. reported that nicotine inhibits IL-18-enhanced expression of ICAM-1 on monocytes (34). Conversely, Cirillo et al. and others demonstrated that nicotine promotes ICAM expression on endothelial cells (35,36). The present study revealed that stimulation of the CAP reduced production of ICAM-1 not only on monocytes but also on leukocytes in the peripheral blood (Fig. 5A). Therefore, based on this finding, it may be hypothesized that the CAP has a dominant influence on monocyte adhesion to endothelial cells.

In conclusion, the results of the present study indicated that activation of the CAP via nicotine stimulation reduces CIA-associated inflammation by decreasing the number of macrophages in synovial tissues, which is mediated by effects not only on the chemotaxis of macrophages but also on macrophage adhesion to endothelial cells. These observations suggest that stimulation of cholinergic signaling potentially serves a key role in initiating and maintaining joint inflammation in patients with RA. Therefore, further investigation regarding the role of CAP in this context is required.

Acknowledgements

The present study was supported by a grant from the National Natural Science Foundation of China (grant no. 81571602).

References

1. Davignon JL, Hayder M, Baron M, Boyer JF, Constantin A, Apparaill F, Padjot R, and Cantagrel A: Targeting monocytes/macrophages in the treatment of rheumatoid arthritis. Rheumatology (Oxford) 52: 590-598, 2013.
2. Kinne RW, Stuhlmüller B and Burmester GR: Cells of the synovium in rheumatoid arthritis. Macrophages. Arthritis Res Ther 9: 224, 2007.
3. Mulherin D, Fitzgerald O and Bresnihan B: Synovial tissue macrophage populations and articular damage in rheumatoid arthritis. Arthritis Rheum 39: 115-124, 1996.
4. Tak PP and Bresnihan B: The pathogenesis and prevention of joint damage in rheumatoid arthritis: Advances from synovial biopsy and tissue analysis. Arthritis Rheum 43: 2619-2633, 2000.
5. Richards PJ, Williams AS, Goodfellow RM and Williams BD: Liposomal clonodermelamine inhibits synovial macrophages, reduces inflammation and ameliorates joint destruction in antigen-induced arthritis. Rheumatology (Oxford) 38: 818-825, 1999.
6. Haringman JJ, Smeets TJ, Reinders-Blankert P and Tak PP: Chemokine and chemokine receptor expression in paired peripheral blood mononuclear cells and synovial tissue of patients with rheumatoid arthritis, osteoarthritis, and reactive arthritis. Ann Rheum Dis 65: 294-300, 2006.
7. Hayashida K, Nanki T, Girschick H, Yavuz S, Ochi T and Lipsky PE: Synovial stromal cells from rheumatoid arthritis patients attract monocytes by producing MCP-1 and IL-8. Arthritis Res 3: 118-126, 2001.
8. Brühl H, Cichak J, Plachý J, Kunz-Schughart L, Niedermeier M, Denzel A, Rodríguez Gomez M, Talke Y, Luckow B, Stangassinger M and Mack M: Targeting of Gr-1, CCR2 monocytes in collagen-induced arthritis. Arthritis Rheum 56: 2975-2985, 2007.
9. Borovikova LV, Ivanova S, Zhang M, Yang H, Botchkina GI, Watkins LR, Wang H, Abumrad N, Eaton JW and Tracey KJ: Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 405: 485-492, 2000.
10. Itstaard C, Collet V, Laterre PF, Leducivc C, Wittebole X and Laterre PF: Electrical vagus nerve stimulation and nicotine effects in periarteritis-induced acute lung injury in rats. Inflammation 34: 29-35, 2011.
11. Zhao M, He X, Bi XY, Yu XJ, Gil Wier W and Zang WJ: Vagal stimulation triggers prophylactic vascular protection through the cholinergic anti-inflammatory pathway in a rat model of myocardial ischemia/reperfusion. Basic Res Cardiol 108: 345, 2013.
12. Wilund KR, Rosenblat M, Chung HR, Volkova N, Kaplan M, Woods JA and Aviram M: Macrophages from alpha 2 nicotinic acetylcholine receptor knockout mice demonstrate increased cholesterol accumulation and decreased cellular paraoxonase expression: A possible link between the nervous system and atherosclerosis development. Biochem Biophys Res Commun 390: 148-154, 2009.
13. Rossa-Ballina M, Goldstein RS, Gallowitsch-Puerta M, Yang L, Valdés-Ferrer HI, Patel NB, Chavan S, Al-Abed Y, Yang H and Tracey KJ: The selective alpha7 agonist GTS-21 attenuates cytokine production in human whole blood and human monocytes activated by ligands for TL2R, TL3R, TL4R, TL9R, and RAGE. Mol Med 15: 195-202, 2009.
14. Li T, Zuo X, Zhou Y, Wang Y, Zhuang H, Zhang L, Zhang H and Xiao X: The vagus nerve and nicotinic receptors involve inhibition of HMGB1 release and early pro-inflammatory cytokines function in collagen-induced arthritis. J Clin Immunol 30: 213-220, 2010.
15. Wu S, Luo H, Xiao X, Zhang H, Li T and Zuo X: Attenuation of collagen induced arthritis via suppression on Th1? response by activating cholinergic anti-inflammatory pathway with nicotine. Eur J Pharmcol 735: 97-104, 2014.
16. van Maanen MA, Lebré MC, van der Poll T, LaRosa GJ, Elbaum D, Vervoordeldonk MJ and Tak PP: Stimulation of nicotinic acetylcholine receptors attenuates collagen-induced arthritis in mice. Arthritis Rheum 60: 114-122, 2009.
17. Szekanecz Z, Koch AE and Tak PP: Chemokine and chemokine receptor blockade in arthritis, a prototype of immune-mediated inflammatory diseases. Neth J Med 69: 356-366, 2011.
18. Katschke KJ Jr, Rottman JB, Ruth JH, Qin S, Wu L, LaRosa G, Ponath P, Park CC, Pope RM and Koch AE: Differential expression of chemokine receptors on peripheral blood, synovial fluid, and synovial tissue monocytes/macrophages in rheumatoid arthritis. Arthritis Rheum 44: 1022-1032, 2001.
19. Tracey KJ: The inflammatory reflex. Nature 420: 853-859, 2002.
20. van Maanen MA, Stoop SP, Larosa GJ, Vervoordeldonk MJ and Tak PP: Role of the cholinergic nervous system in rheumatoid arthritis: Aggravation of arthritis in nicotinic acetylcholine receptor α7 subunit gene knockout mice. Ann Rheum Dis 69: 1717-1723, 2010.
21. Wu S, Zhao H, Luo H, Xiao X, Zhang H, Li T and Zuo X: GTS-21, an α7-nicotinic acetylcholine receptor agonist, modulates Th1 differentiation in CD4+ T cells from patients with rheumatoid arthritis. Exp Ther Med 8: 557-562, 2014.
22. Haringman JJ, Gerlag DM, Zwinderman AH, Smeets TJ, Kraan MC, Baeten D, McInnes IB, Bresnihan B and Tak PP: Synovial tissue macrophages: A sensitive biomarker for response to treatment in patients with rheumatoid arthritis. Ann Rheum Dis 64: 834-838, 2005.
23. Abeles AM and Pillinger MH: The role of the synovial fibroblast in rheumatoid arthritis: Cartilage destruction and the regulation of matrix metalloproteinases. Bull NYU Hosp Jt Dis 64: 20-24, 2006.
24. Kennedy A, Fearon U, Veale DJ and Godson C: Macrophages in synovial inflammation. Front Immunol 2: 52, 2011.
25. Koch AE, Kunkel SL, Harlow LA, Mazarakis DD, Haines GK, Burdick MD, Pope RM and Strieter RM: Macrophage inflammatory protein-1 alpha. A novel chemotactic cytokine for macrophages in rheumatoid arthritis. J Clin Invest 93: 921-928, 1994.
26. Luther SA and Cyster JG: Chemokines as regulators of T cell differentiation. Nat Immunol 2: 102-107, 2001.
27. Shahrra S, Proudfoot AE, Park CC, Volin MV, Haines GK, Woods JM, Aikens CH, Handel TM and Pope RM: Inhibition of monocyte chemotactant protein-1 ameliorates rat adjuvant-induced arthritis. J Immunol 180: 3447-3456, 2008.
28. Haringman JJ, Ludikhuize J and Tak PP: Chemokines in joint disease: The key to inflammation? Ann Rheum Dis 63: 1186-1194, 2004.
29. Geissmann F, Jung S and Littman DR: Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 19: 71-82, 2003.
30. Jiménez-Sainz MC, Fast B, Mayor F Jr and Aragy AM: Signaling pathways for monocyte chemotactic protein 1-mediated extracellular signal-regulated kinase activation. Mol Pharmacol 64: 773-782, 2003.
31. Brühl H, Cihak J, Schneider MA, Plachý J, Rupp T, Wenzel I, Shakarami M, Milz S, Ellwart JW, Stangassinger M, et al: Dual role of CCR2 during initiation and progression of collagen-induced arthritis: Evidence for regulatory activity of CCR2+ T cells. J Immunol 172: 890-898, 2004.
32. Haringman JJ, Kraan MC, Smeets TJ, Zwinderman KH and Tak PP: Chemokine blockade and chronic inflammatory disease: Proof of concept in patients with rheumatoid arthritis. Ann Rheum Dis 62: 715-721, 2003.
33. Amat M, Benjamim CF, Williams LM, Prats N, Terricabras E, Beleta J, Kunkel SL and Godessart N: Pharmacological blockade of CCR1 ameliorates murine arthritis and alters cytokine networks in vivo. Br J Pharmacol 149: 666-675, 2006.
34. Takahashi HK, Iwagaki H, Hamano R, Yoshino T, Tanaka N and Nishibori M: Effect of nicotine on IL-18-initiated immune response in human monocytes. J Leukoc Biol 80: 1388-1394, 2006.
35. Cirillo P, Pacileo M, De Rosa S, Calabrò P, Gargiulo A, Angri V, Prevete N, Fiorentino I, Ucci G, Sasso L, et al: HMG-CoA reductase inhibitors reduce nicotine-induced expression of cellular adhesion molecules in cultured human coronary endothelial cells. J Vasc Res 44: 460-470, 2007.
36. Breen LT, McHugh PE and Murphy BP: HUVEC ICAM-1 and VCAM-1 synthesis in response to potentially athero-prone and athero-protective mechanical and nicotine chemical stimuli. Ann Biomed Eng 38: 1880-1892, 2010.